What clinical trials are available for metastatic Lung Cancer

Clinical Trials for Metastatic Lung Cancer

I appreciate your question about clinical trial options. While I have access to comprehensive NCCN Guidelines for lung cancer treatment, I should be transparent: the specific guidelines provided don't include a detailed registry of currently active clinical trials with enrollment information.

However, I can explain what the evidence shows about trial-tested treatments and direct you to where you can find active trials.

What the Evidence Shows About Metastatic NSCLC Trials

According to NCCN Guidelines for Non-Small Cell Lung Cancer, several major treatment approaches have been validated through clinical trials:

Immunotherapy Trials:

• PD-1/PD-L1 inhibitors (like pembrolizumab) have shown response rates around 33% in patients with brain metastases from lung cancer
• Combination immunotherapy approaches (like ipilimumab/nivolumab) are being studied for various metastatic presentations

Targeted Therapy Trials:

• EGFR mutations: Trials comparing erlotinib, gefitinib, and afatinib as first-line treatments
• ALK rearrangements: Crizotinib and newer ALK inhibitors
• MET alterations: Capmatinib and tepotinib for MET-amplified disease
• RET fusions: Selpercatinib (LIBRETTO-001 trial showed good intracranial response)
• BRAF mutations: Vemurafenib and combination BRAF/MEK inhibitor approaches

Combination Approaches:

• Chemotherapy plus immunotherapy combinations
• Targeted therapy with continuation of prior effective agents

How to Find Active Trials for YOUR Situation

Best Resources:

1. ClinicalTrials.gov (https://clinicaltrials.gov)

   • Search: "metastatic non-small cell lung cancer"
   • Filter by: your location, your specific biomarkers (EGFR, ALK, PD-L1 status, etc.)
   • Shows enrollment status and contact information

2. NCCN Member Institutions

   • NCCN Guidelines recommend checking with major cancer centers
   • These centers typically have active trials aligned with current evidence

3. Your Oncology Team

   • They can identify trials matching YOUR specific:
     • Tumor biomarkers (EGFR, ALK, PD-L1, MET, RET, BRAF status)
     • Prior treatments received
     • Performance status
     • Organ function

4. Cancer-Specific Resources:

   • American Cancer Society: cancer.org/research/clinical-trials
   • Lung Cancer Alliance: lungcanceralliance.org
   • LUNGevity Foundation: lungevity.org

Questions to Ask Your Oncologist About Trials

1. "Are there any active trials at this institution that match my tumor's biomarkers?"

2. "Based on my prior treatments, which trials would be appropriate for me?"

3. "What are the eligibility requirements (organ function, performance status, prior therapy lines)?"

4. "How does this trial compare to standard treatment options for my situation?"

5. "What are the potential benefits and side effects specific to this trial?"

6. "Will the trial be at a convenient location, and what does participation involve?"

Important Context

According to NCCN Guidelines, the choice between standard treatment and clinical trials depends on:

• Your specific biomarkers (which drive treatment selection)
• Number of prior treatment lines
• Current organ function and performance status
• Whether novel agents in trials might offer advantages over established options

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.